TY - JOUR
T1 - Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides
T2 - A Surveillance, Epidemiology, and End Results analysis
AU - Goyal, Amrita
AU - O'Leary, Daniel
AU - Goyal, Kavita
AU - Rubin, Nathan
AU - Bohjanen, Kimberly
AU - Hordinsky, Maria
AU - Chen, Steven T.
AU - Pongas, Georgios
AU - Duncan, Lyn M.
AU - Lazaryan, Aleksandr
N1 - Publisher Copyright:
© 2019 American Academy of Dermatology, Inc.
PY - 2020/8
Y1 - 2020/8
N2 - BACKGROUND: Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized.OBJECTIVE: This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF.DESIGN: We performed an analysis of patients diagnosed with MF from 2000 through 2015 in the United States cancer registries of SEER-18 (N = 6742).RESULTS: Relative risks were estimated by using standardized incidence ratios (SIRs). Among 6742 patients, there were 511 (7.5%) second cancer events (SIR, 10.15; 95% confidence interval [CI], 9.29-11.07). These included 184 (36.0%) hematologic malignancies (SIR, 39.71; 95% CI, 34.05-46.05) and 327 (64.0%) solid tumor malignancies (SIR, 7.33; 95% CI, 6.56-8.17). Patients with MF were at increased risk for non-Hodgkin lymphoma; Hodgkin lymphoma; melanoma; and lung, female breast, prostate, colon, and renal cancers. Females were at higher risk than males (P < .05). All ethnic groups showed a statistically significant elevation in SIRs. Elevation of SIRs was observed across all stages of MF.CONCLUSIONS AND RELEVANCE: Patients with MF are at increased risk for diagnosis of second primary malignancies and should be carefully screened for discernable signs and symptoms of second malignancies.
AB - BACKGROUND: Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized.OBJECTIVE: This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF.DESIGN: We performed an analysis of patients diagnosed with MF from 2000 through 2015 in the United States cancer registries of SEER-18 (N = 6742).RESULTS: Relative risks were estimated by using standardized incidence ratios (SIRs). Among 6742 patients, there were 511 (7.5%) second cancer events (SIR, 10.15; 95% confidence interval [CI], 9.29-11.07). These included 184 (36.0%) hematologic malignancies (SIR, 39.71; 95% CI, 34.05-46.05) and 327 (64.0%) solid tumor malignancies (SIR, 7.33; 95% CI, 6.56-8.17). Patients with MF were at increased risk for non-Hodgkin lymphoma; Hodgkin lymphoma; melanoma; and lung, female breast, prostate, colon, and renal cancers. Females were at higher risk than males (P < .05). All ethnic groups showed a statistically significant elevation in SIRs. Elevation of SIRs was observed across all stages of MF.CONCLUSIONS AND RELEVANCE: Patients with MF are at increased risk for diagnosis of second primary malignancies and should be carefully screened for discernable signs and symptoms of second malignancies.
KW - CTCL
KW - SEER
KW - Surveillance Epidemiology and End Results
KW - cutaneous T-cell lymphoma
KW - cutaneous lymphoma
KW - mycosis fungoides
KW - non-Hodgkin lymphoma
KW - second malignancy
UR - http://www.scopus.com/inward/record.url?scp=85073719817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073719817&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2019.07.075
DO - 10.1016/j.jaad.2019.07.075
M3 - Article
C2 - 31374302
AN - SCOPUS:85073719817
SN - 0190-9622
VL - 83
SP - 404
EP - 411
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 2
ER -
